Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2026-03-05 06:08 am Purchase | 2025-12-31 | 13G | ARRIVENT BIOPHARMA INC AVBP | Sofinnova Venture Partners XI, L.P. ("SVP XI") | 1,696,752 4.100% | 1,696,752 (New Position) | Filing History |
| 2026-03-05 06:06 am Sale | 2025-12-19 | 13D | NEXTCURE INC NXTC | Sofinnova Venture Partners XI, L.P. ("SVP XI") | 222,654 7.100% | -2,449,202 (-91.67%) | Filing History |
| 2024-02-20 6:57 pm Sale | 2023-02-16 | 13D | GALERA THERAPEUTICS INC GRTX | Sofinnova Venture Partners XI, L.P. ("SVP XI") | 0 0.000% | -3,083,712 (Position Closed) | Filing History |
| 2023-02-03 7:04 pm Sale | 2022-11-09 | 13D | GALERA THERAPEUTICS INC GRTX | Sofinnova Venture Partners XI, L.P. ("SVP XI") | 3,083,712 10.800% | -1,098 (-0.04%) | Filing History |